Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead Sciences stock focuses on liver data in week ahead

Clinical trial results Research milestone AI-generated analysis

πŸ“… Gilead Sciences will present its scientific program at The Liver Meeting 2026 in Denver from November 5 to November 9.

πŸ’Š The presentation highlights late-breaking Phase 3 research for Livdelzi (seladelpar) regarding composite alkaline phosphatase normalization in primary biliary cholangitis.

πŸ”¬ Gilead plans to share long-term evidence and real-world data for Hepcludex (bulevirtide) treating chronic hepatitis delta virus infection.

πŸ“Š The company has secured 21 accepted abstracts covering safety, efficacy, fatigue, renal function, and treatment adherence metrics.

πŸ—£οΈ Abstract 5007 on Livdelzi is scheduled as an oral presentation on Sunday, November 8, from 5:00 to 5:15 p.m. Denver time.

πŸ“ˆ The event offers investors a scheduled readout on clinical development and patient outcomes rather than immediate earnings data.

πŸ’° Gilead Sciences stock traded at 152.76 euros on November 1, down 1.01% from the Friday close of 154.32 euros.

πŸ₯ Research topics include integrated efficacy findings and non-invasive fibrosis testing for Hepcludex patients.

πŸ“‰ The business relevance depends on how presented evidence affects market expectations for Livdelzi and Hepcludex adoption.

Bullish Signals
  • Gilead Sciences will present late-breaking Phase 3 research for Livdelzi (seladelpar) at The Liver Meeting, providing new data on composite alkaline phosphatase normalization.
  • The company plans to showcase long-term and real-world evidence for Hepcludex (bulevirtide), demonstrating sustained efficacy in chronic hepatitis delta treatment.
  • Gilead has secured 21 accepted abstracts covering comprehensive metrics including five-year safety, fatigue management, renal function, and treatment adherence.
  • The presentation includes specific analyses on portal hypertension after 48 weeks of Hepcludex treatment and disease progression in chronic hepatitis delta.
Full Analysis
Gilead Sciences is preparing to present new clinical and real-world evidence at The Liver Meeting 2026 in Denver, scheduled from November 5 through November 9. The company announced this scientific program on October 22, focusing on its research into primary biliary cholangitis (PBC) and chronic hepatitis delta virus infection. The core of the presentation will feature late-breaking Phase 3 data for Livdelzi (seladelpar), specifically regarding composite alkaline phosphatase normalization. Additionally, Gilead plans to showcase long-term efficacy and safety profiles for Hepcludex (bulevirtide) in treating chronic hepatitis delta, including analyses on portal hypertension and disease progression. For investors, this event serves as a critical readout for clinical development progress rather than an earnings report. The market relevance will hinge on how the presented data influences expectations for Livdelzi and Hepcludex adoption in their respective therapeutic markets, potentially impacting future revenue guidance and stock performance. Gilead Sciences stock was trading at 152.76 euros on November 1, reflecting a slight decline of 1.01% against the previous Friday's close. While US equities like the S&P 500 provide the broader market backdrop, the specific focus remains on the company's pipeline advancements in liver disease treatments presented at the upcoming conference.